Between 2000 and 2014, an estimated 1.3 million new HIV infections have been averted by prevention of mother-to-child transmission programmes in all low- and middle-income countries.
New HIV infections among children peaked at half a million in 2001. The advent of antiretroviral treatment and the roll-out of prevention of mother-to-child transmission programmes has cut the number of new infections.
Like many countries in Eastern Europe and Central Asia, the HIV epidemic is largely driven by injecting drug use. But an active civil society in the Ukraine has had major success in turning around the epidemic among people who inject drugs.
In 2001, Indian generic drug manufacturer Cipla announces that it will sell a generic copy of a triple-therapy antiretroviral (ARV) for US $350 per patient per year. This has an incredible impact.
The years 2002-2008 see a significant increase in funding for the global HIV response from donor governments. However, since then funding has more or less flat-lined.
Average life expectancy across many parts of sub-Saharan Africa plummets as a result of the HIV epidemic. But after generics become available, countries start antiretroviral programmes which bring about improvements in life expectancy.